Clinical Trial Update: Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients [Phase 3]

View source ↗

Summary

This entry provides an update on a Phase 3 clinical trial evaluating alemtuzumab for stabilizing neurocognitive function in relapsing-remitting multiple scleros…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Lemtrada (alemtuzumab)

Snippet

Sponsor: Central Texas Neurology Consultants | Conditions: Multiple Sclerosis | Phase 3 | Status: UNKNOWN